Biogen is a global biopharmaceutical company focused on discovering, developing, and delivering innovative therapies for people living with serious and complex diseases worldwide. The company has a broad portfolio of medicines to treat MS, has introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer's disease and launched the first approved treatment to target a genetic cause of ALS. Biogen is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. The company supports its drug discovery and development efforts through internal research and development programs and external collaborations.

• Employees: 7,570 (as of December 31, 2023)
• Geographic Footprint: Operates worldwide, including in the U.S., Europe and Japan
• Headquarters: Cambridge, MA
• Founded: Not explicitly stated in the 10K
• Number of locations/facilities: Multiple manufacturing facilities, including in RTP, North Carolina and Solothurn, Switzerland
• Revenue: $9.8 billion (FY2023)
• Market Capitalization: $41.1 billion (as of the last business day of the most recently completed second fiscal quarter)
• Key Subsidiaries/Brands: Includes brands such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, SPINRAZA, SKYCLARYS, QALSODY, FUMADERM, BENEPALI, IMRALDI, FLIXABI, BYOOVIZ, TOFIDENCE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI.

• CEO: Christopher A. Viehbacher
• CFO: Michael R. McDonnell
• Chief Legal Officer: Susan H. Alexander
• Head of Research: Jane Grogan, Ph.D.
• Head of Corporate Development: Adam Keeney, Ph.D.
• Board Chair: Caroline Dorsa

Key leaders have extensive experience in the biopharmaceutical industry and related fields.

• Annual Revenue: $9.8 billion (FY2023)
• Net Income: $1.2 billion (FY2023)
• Market Cap: $41.1 billion (as of the last business day of the most recently completed second fiscal quarter)
• Total Assets: $26.8 billion (as of December 31, 2023)
• Number of Employees: 7,570 (as of December 31, 2023)
• Key Financial Highlights: Revenue decreased by 3.3% year-over-year, net income decreased by 61.8% year-over-year.

Biogen's main product categories are:

• Multiple Sclerosis (MS) Therapies: Includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA.
• Rare Disease Therapies: Includes SPINRAZA for SMA, SKYCLARYS for Friedreich's Ataxia, and QALSODY for ALS.
• Biosimilars: Includes BENEPALI, IMRALDI, FLIXABI, BYOOVIZ and TOFIDENCE.
• Anti-CD20 Therapeutic Programs: Includes RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and LUNSUMIO.
• Other: Includes FUMADERM, ADUHELM and ZURZUVAE.

These products address a range of serious and complex diseases.

The company operates as one segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Revenue breakdown by therapeutic area is as follows:

• Multiple Sclerosis (MS): $4.7 billion (FY2023)
• Rare Disease: $1.8 billion (FY2023)
• Biosimilars: $0.8 billion (FY2023)
• Anti-CD20 Therapeutic Programs: $1.7 billion (FY2023)
• Other: $0.1 billion (FY2023)

Biogen's strategy is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Key initiatives include:

• Advancing the development of new pharmaceutical products and technologies.
• Exploring strategic options for its biosimilars business.
• Committing significant resources to targeted research and development opportunities.
• Seeking to improve operating efficiency and effectiveness through its Fit for Growth program.
• Continuing to evaluate opportunities for acquiring products or rights to products and technologies that are complementary to its business.

Biogen operates in the biopharmaceutical industry, which is characterized by intense competition. Key aspects of the industry include:

• Primary Industry: Biopharmaceutical
• Market Trends: Increasing competition from generics, biosimilars, and new therapies, as well as pricing pressures.
• Key Competitors: Includes companies such as Sanofi Genzyme, Bayer Group, Novartis AG, and Genentech, among others.
• Market Share: Not explicitly stated in the 10K.

• Competition: The company faces intense competition from other pharmaceutical companies, including generics and biosimilars, which may reduce the price and volume of its products.
• Product Development: The company's success depends on the successful development of new products, which involves significant risk and may not be successful.
• Pricing and Reimbursement: The company's revenue depends on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing pressure.
• Intellectual Property: The company's ability to protect its intellectual property rights is critical, and challenges to its patents or regulatory exclusivities could negatively impact its business.
• Manufacturing: Manufacturing issues could substantially increase costs, limit supply of products and/or reduce revenue.